Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Rigel Pharmaceuticals, Inc.”

373 pharma patents match "Rigel Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 373
Index total 30,257
Page 15 / 16

Quick answer

This filtered view shows 373 pharmaceutical patents matching "Rigel Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

373 results for “Rigel Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 7422867

    Methods of identifying compounds that modulate IL-4 receptor mediated IgE synthesis utilizing a CLLD8 protein

    Rigel Pharmaceuticals, Inc. · Granted Sep 9, 2008 · Expires Sep 4, 2028

    granted
  2. US 7420045

    IAPs associated cell cycle proteins, compositions and methods of use

    Rigel Pharmaceuticals, Inc. · Granted Sep 2, 2008 · Expires Aug 28, 2028

    granted
  3. US 7413870

    SAK: modulation of cellular proliferation for treatment of cancer

    Rigel Pharmaceuticals, Inc. · Granted Aug 19, 2008 · Expires Aug 14, 2028

    granted
  4. US 7410979

    Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections

    Rigel Pharmaceuticals, Inc. · Granted Aug 12, 2008 · Expires Aug 7, 2028

    granted
  5. US 7378251

    Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a thioredoxin-like 32 kDa protein

    Rigel Pharmaceuticals, Inc. · Granted May 27, 2008 · Expires May 22, 2028

    granted
  6. US 7368257

    Modulators of lymphocyte activation, Mkk3b compositions and methods of use

    Rigel Pharmaceuticals, Inc. · Granted May 6, 2008 · Expires May 1, 2028

    granted
  7. US 7358259

    HCV inhibitors and methods of using them

    Rigel Pharmaceuticals, Inc. · Granted Apr 15, 2008 · Expires Apr 10, 2028

    granted
  8. US 7332484

    2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Feb 19, 2008 · Expires Feb 14, 2028

    granted
  9. US 7332602

    Pyridyl substituted heterocycles useful for treating or preventing HCV infection

    Rigel Pharmaceuticals, Inc. · Granted Feb 19, 2008 · Expires Feb 14, 2028

    granted
  10. US 7329672

    2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Feb 12, 2008 · Expires Feb 7, 2028

    granted
  11. US 7329671

    2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Feb 12, 2008 · Expires Feb 7, 2028

    granted
  12. US 7326790

    Diphenylisoxazole compounds and hydro isomers thereof

    Rigel Pharmaceuticals, Inc. · Granted Feb 5, 2008 · Expires Jan 31, 2028

    granted
  13. US 7285383

    Method for selective inactivation of viral replication

    Rigel Pharmaceuticals, Inc. · Granted Oct 23, 2007 · Expires Oct 18, 2027

    granted
  14. US 7244576

    Modulators of angiogenesis

    Rigel Pharmaceuticals, Inc. · Granted Jul 17, 2007 · Expires Jul 12, 2027

    granted
  15. US 7241581

    Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a c-MYC protein

    Rigel Pharmaceuticals, Inc. · Granted Jul 10, 2007 · Expires Jul 5, 2027

    granted
  16. US 7220745

    Heterocyclic compounds useful to treat HCV

    Rigel Pharmaceuticals, Inc. · Granted May 22, 2007 · Expires May 17, 2027

    granted
  17. US 7208289

    Methods of identifying compounds that modulate IL-4 receptor mediated IgE synthesis utilizing a CLLD8 protein

    Rigel Pharmaceuticals, Inc. · Granted Apr 24, 2007 · Expires Apr 19, 2027

    granted
  18. US 7157473

    Pyridyl substituted heterocycles useful for treating or preventing HCV infection

    Rigel Pharmaceuticals, Inc. · Granted Jan 2, 2007 · Expires Dec 28, 2026

    granted
  19. US 7153880

    Substituted diphenyl heterocycles useful for treating HCV infection

    Rigel Pharmaceuticals, Inc. · Granted Dec 26, 2006 · Expires Dec 21, 2026

    granted
  20. US 7141434

    Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing an adenosine kinase

    Rigel Pharmaceuticals, Inc. · Granted Nov 28, 2006 · Expires Nov 23, 2026

    granted
  21. US 7122542

    Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

    Rigel Pharmaceuticals, Inc. · Granted Oct 17, 2006 · Expires Oct 12, 2026

    granted
  22. US 7060827

    Intermediates useful for making 2,4-pyrimidinediamine compounds

    Rigel Pharmaceuticals, Inc. · Granted Jun 13, 2006 · Expires Jun 8, 2026

    granted
  23. US 7045284

    Method for selective inactivation of viral replication

    Rigel Pharmaceuticals, Inc. · Granted May 16, 2006 · Expires May 11, 2026

    expired
  24. US 6979549

    Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a CLLD8 protein

    Rigel Pharmaceuticals, Inc. · Granted Dec 27, 2005 · Expires Dec 22, 2025

    expired